1707 related articles for article (PubMed ID: 16957514)
1. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
[TBL] [Abstract][Full Text] [Related]
2. Survey of internal medicine residents' use of the fecal occult blood test and their understanding of colorectal cancer screening and surveillance.
Sharma VK; Corder FA; Raufman JP; Sharma P; Fennerty MB; Howden CW
Am J Gastroenterol; 2000 Aug; 95(8):2068-73. PubMed ID: 10950059
[TBL] [Abstract][Full Text] [Related]
3. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.
Sharma VK; Corder FA; Fancher J; Howden CW
Am J Gastroenterol; 2000 Dec; 95(12):3629-32. PubMed ID: 11151904
[TBL] [Abstract][Full Text] [Related]
4. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
[TBL] [Abstract][Full Text] [Related]
5. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
Lieberman DA; Weiss DG;
N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
[TBL] [Abstract][Full Text] [Related]
6. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
7. Measuring the quality of colorectal cancer screening: the importance of follow-up.
Etzioni DA; Yano EM; Rubenstein LV; Lee ML; Ko CY; Brook RH; Parkerton PH; Asch SM
Dis Colon Rectum; 2006 Jul; 49(7):1002-10. PubMed ID: 16673056
[TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer test use--Maryland, 2002-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Sep; 56(36):932-6. PubMed ID: 17851446
[TBL] [Abstract][Full Text] [Related]
9. Screening colonoscopy and fecal occult blood testing practice patterns: a population-based survey of gastroenterologists.
Rossi F; Sosa JA; Aslanian HR
J Clin Gastroenterol; 2008; 42(10):1089-94. PubMed ID: 18936643
[TBL] [Abstract][Full Text] [Related]
10. The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening.
Almog R; Ezra G; Lavi I; Rennert G; Hagoel L
Eur J Cancer Prev; 2008 Oct; 17(5):430-7. PubMed ID: 18714185
[TBL] [Abstract][Full Text] [Related]
11. Patient perceptions of stool-based DNA testing for colorectal cancer screening.
Schroy PC; Heeren TC
Am J Prev Med; 2005 Feb; 28(2):208-14. PubMed ID: 15710277
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
[TBL] [Abstract][Full Text] [Related]
13. Colonoscopy: a review of its yield for cancers and adenomas by indication.
Rex DK
Am J Gastroenterol; 1995 Mar; 90(3):353-65. PubMed ID: 7872270
[TBL] [Abstract][Full Text] [Related]
14. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
Quintero E
Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
[TBL] [Abstract][Full Text] [Related]
15. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
[TBL] [Abstract][Full Text] [Related]
16. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
[TBL] [Abstract][Full Text] [Related]
18. Lower gastrointestinal symptoms are not predictive of colorectal neoplasia in a faecal occult blood screen-positive population.
Ahmed S; Leslie A; Thaha MA; Carey FA; Steele RJ
Br J Surg; 2005 Apr; 92(4):478-81. PubMed ID: 15609377
[TBL] [Abstract][Full Text] [Related]
19. [Individual screening for colorectal cancer: which strategy for which patient?].
Demols A; Van Laethem JL; Gay F; Franchimont D; Adler M; Van Gossum A
Rev Med Brux; 2001 Sep; 22(4):A203-9. PubMed ID: 11680174
[TBL] [Abstract][Full Text] [Related]
20. [Colorectal cancer screening programs in the population at average risk in the European Union and Spain].
Grau J; Serradesanferm A; Polbach S; García-Basteiro AL; Trilla A; Castells A
Gastroenterol Hepatol; 2010 Feb; 33(2):111-8. PubMed ID: 19523716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
